一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制评价结果推测未来内部控制的有效性具有一定的风险。 二. 内部控制评价结论 1. 公司于内部控制评价报告基准日，是否存在财务报告内部控制重大缺陷 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2024年度内部控制评价报告 上海神奇制药投资管理股份有限公司全体股东： 根据《企业内部控制基本规 ...

证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2025-010 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 2025 年第一季度主要运营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、运营数据 1．主营业务分行业情况 单位：元 1 分行业 2025年 1-3月营业 收入 2025 年 1-3 月营 业成本 毛利率 （%） 营业收 入比上 年同期 增减（%） 营业成 本比上 年同期 增减（%） 毛利率 比上年 同期增 减（%） 一、医药制造 274,211,549.66 72,209,058.64 73.67 -21.05 -15.26 -1.80 二、医药商业 205,715,284.98 183,258,206.18 10.92 -9.47 -11.36 1.91 合计 479,926,834.64 255,467,264.82 46.77 -16.47 -12.50 -2.41 2．主营业务分类情况 单位：元 分产品 营业收入 营业成本 毛利率 （% ...

| | | 上海神奇制药投资管理股份有限公司 关于续聘审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●拟续聘的审计机构名称：立信会计师事务所（特殊普通合伙） 上海神奇制药投资管理股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第十一届董事会第八次会议，审议通过了《关于续聘审计机构的议案》， 经董事会审计委员会提议，公司拟聘请立信会计师事务所（特殊普通合伙）（以 下简称"立信"）为公司 2025 年度审计机构，并提请股东大会授权公司管理层 确定其审计费用，聘期为 1 年。公司现将具体情况公告如下： 一、拟聘请会计师事务所的基本情况 （一）机构信息 1.基本信息 立信由我国会计泰斗潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会计师事务所，注册地址为上海市。 立信是国际会计网络 BDO 的成员所，长期从事证券服务业务，新证券法实施前 具有证券、期货业务许可证，具有 H 股审计资格，并已向美国公众公司会计监 督委员 ...

2.人员信息 截至 2024 年末，立信拥有合伙人 296 名、注册会计师 2,498 名、从业人 员总数 10,021 名，签署过证券服务业务审计报告的注册会计师 743 名。立信 2024 年业务收入（未经审计）50.01 亿元，其中审计业务收入 35.16 亿元，证 券业务收入 17.65 亿元。首席合伙人为朱建弟先生。 3.业务规模 上海神奇制药投资管理股份有限公司 董事会审计委员会对会计师事务所 2024 年度履职情况评估 及履行监督职责情况的报告 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司治 理准则》、《国有企业、上市公司选聘会计师事务所管理办法》、《上海证券交易所 关于上市公司做好选聘会计师事务所工作的提醒》、《公司章程》、《董事会专门委 员会工作细则》等规定和要求，董事会审计委员会（以下简称"审计委员会"） 本着勤勉尽责的原则，恪尽职守，认真履职，对公司年审会计师事务所立信会计 师事务所（特殊普通合伙）（以下简称"立信"）2024 年的审计资质及工作履行 了监督职责，现将情况汇报如下： 一、2024 年度会计师事务所基本情况 1.基本信息 立信由我国会计泰斗潘序伦博士于 ...

900904 神奇 B 股 证券代码：600613 证券简称：神奇制药 公告编号：2025-009 上海神奇制药投资管理股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 16 日 9 点 30 分 召开地点：贵州省贵阳市观山湖区毕节路 58 号联合广场 1 号楼 37 层会议室 1 股东大会召开日期：2025年5月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 16 日 至2025 年 5 月 16 日 采用上海证券交易所网络投票系统，通过 ...

| 证券代码：A | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | B | | | | | | | 股 股 | | | | | | | | | | | | 600613 900904 | | | | | | | | | | | | 股票简称：A | | | | | | | | | | | | | | | 神奇制药 神奇 B 股 | | | | | | | | | | | | 编号： | 2025-005 | | | | | | B | | | | | | | | | | | | | 股 股 | | | | 上海神奇制药投资管理股份有限公司 第十一届监事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届监事会 第八次会议通知已于 2025 年 4 月 14 日分别以传真、邮件、短信等方式通知全体 监事。根据《 ...

| | | 上海神奇制药投资管理股份有限公司 第十一届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届董事会 第八次会议通知已于 2025 年 4 月 14 日分别以送达、传真、邮件等方式通知公司 董事、监事。会议于 2025 年 4 月 24 日在贵阳市观山湖区毕节路 58 号联合广场 1 号楼 39 层会议室以现场表决方式召开。应参会董事 9 人，现场参会董事 9 人。 公司监事和部分高管人员列席了会议。会议由公司董事长 ZHANGTAOTAO 先生主持。 会议符合《公司法》及《公司章程》的有关规定，会议及表决合法有效。经审议， 会议通过如下决议： 一、审议通过《公司 2024 年度总经理工作报告》 表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、审议通过《公司 2024 年度董事会工作报告》 董事会审议通过了本议案，并同意提交公司 2024 年年度股东大会审议。 三、审议通过《公司 2024 年度报告及报告摘要》 公司董 ...

| 证券代码：A | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | B | | | | | | | | | | | | 股 股 | | | | | | | | | | | | 600613 900904 | 股票简称：A | B | | | | | | | | | | | | 股 股 | | | | | | | | | | | | 神奇制药 神奇 B 股 | | | | | | | | | | | | 编号： | 2025-006 | 上海神奇制药投资管理股份有限公司 关于 2024 年度利润分配方案及提请股东大会授权董 事会制定 2025 年中期分红方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 分配比例：每 10 股派发现金红利 1.5 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。 在实施权益分派的股权登记 ...

Financial Performance - The company's operating revenue for 2024 was CNY 2,048,808,450.63, a decrease of 12.48% compared to CNY 2,340,945,518.00 in 2023[23] - The net profit attributable to shareholders for 2024 increased by 25.24% to CNY 71,388,047.35 from CNY 57,000,674.55 in 2023[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 was CNY 71,121,491.20, up 44.84% from CNY 49,103,973.11 in 2023[23] - The net cash flow from operating activities for 2024 was CNY 207,785,516.12, a decrease of 3.62% compared to CNY 215,590,355.95 in 2023[23] - The total assets at the end of 2024 were CNY 3,115,812,628.78, down 4.99% from CNY 3,279,335,678.82 at the end of 2023[23] - The net assets attributable to shareholders at the end of 2024 were CNY 2,363,038,500.50, an increase of 1.18% from CNY 2,335,387,196.13 at the end of 2023[23] - Basic earnings per share increased by 18.18% to CNY 0.13 compared to CNY 0.11 in the same period last year[24] - The weighted average return on equity increased by 0.59 percentage points to 3.01% compared to 2.42% in the previous year[24] Operational Strategy - The company aims to enhance operational control and promote strategic layout amidst rapidly changing industry policies and market conditions[32] - The marketing strategy focuses on maintaining market share while adapting to the evolving healthcare policies and market dynamics[33] - The company is committed to optimizing its organizational structure and enhancing digital applications to support data-driven decision-making[32] - The company aims to enhance the market share of prescription drugs and explore new business models to improve profitability in 2024[35] - In 2024, the company will deepen the refined management of over-the-counter drug marketing, establishing strategic partnerships with over 200 major chain enterprises[36] - The company is focusing on building a professional marketing team, emphasizing talent specialization and management refinement to adapt to market competition and consumer demand[36] - The company is strengthening its commercial control and risk management systems to ensure deep and broad coverage of its products in medical terminals[37] Research and Development - In 2024, the company will continue to upgrade its product strategy and increase R&D efforts, focusing on strong competitive products and evidence-based medicine research[38] - The company has made significant breakthroughs in the industrialization of potential products, which have become new sales growth points[39] - The company is advancing clinical research on its leading oncology products to enhance their core competitive advantages and drive steady sales growth[39] - The company has established a multi-level R&D system and collaborates with major hospitals for clinical research and product development[63] - The company has advanced equipment and facilities for research, development, and pilot production, supporting new drug development and process standard improvements[116] - The company has completed addiction analysis studies for its products, including the safety studies for Sodium Cantharidinate Injection[116] - Major R&D projects included anti-tumor drug research with an investment of 21,418,807.06 RMB, showing a year-on-year increase of 157.10%[126] Market Trends and Challenges - The pharmaceutical manufacturing industry in China is projected to see a revenue decline of 3.7% in 2024, with total revenue expected to reach CNY 25,205.7 billion[48] - The total profit for the pharmaceutical manufacturing sector is forecasted to decrease by 15.1% in 2024, amounting to CNY 3,473.0 billion[48] - The Chinese pharmaceutical market is experiencing a shift, with the market share of chemical generics declining from 60% to 52% due to the rise of innovative drugs[50] - The national drug procurement policy has led to significant savings, with approximately CNY 4.4 trillion saved since 2018, primarily benefiting innovative drug payments[52] - The average price drop for the third batch of national Chinese medicine procurement was 63%, marking a higher reduction compared to previous batches[53] - The pharmaceutical manufacturing industry is expected to experience a slowdown in growth in 2024, influenced by various regulatory reforms and cost control measures[104] Risk Management - The company is committed to risk management through a cycle of risk identification, assessment, and continuous improvement to mitigate various risks[42] - The company acknowledges risks from policy changes in the pharmaceutical industry, which may impact sales and operational models, and is prepared to adjust strategies accordingly[161] - The fluctuation of raw material prices poses a significant risk to production costs, influenced by macroeconomic factors, natural disasters, and supply chain issues[165] - The company plans to strengthen market price monitoring and analysis, and implement strategic reserve purchasing to mitigate procurement costs[165] - Quality control risks arise from complex production processes and stringent regulatory standards, which could affect brand reputation[169] Corporate Governance - The company has established a system for insider information management to maintain disclosure fairness and compliance with regulations[179] - The total remuneration for the board of directors and senior management during the reporting period amounts to 1,877,720 yuan[184] - The company has a transparent information disclosure system to ensure all shareholders receive timely and accurate information[178] - The board of directors held three meetings during the year, with all members present at each meeting[192] - The audit committee convened five meetings during the reporting period, reviewing key financial reports and internal control evaluations[194][195] Employee Management - The company has a total of 1,266 employees, with 1,260 in major subsidiaries and 6 in the parent company[197] - The employee composition includes 589 production personnel, 141 sales personnel, 256 technical personnel, 62 financial personnel, and 218 administrative personnel[197] - The company has established a salary policy that links employee remuneration to company and individual performance, with a focus on industry salary benchmarks[198] - The company plans to optimize its salary system based on operational results and market conditions to enhance employee benefits[198]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 479,926,834.64, a decrease of 16.47% compared to CNY 574,528,830.84 in the same period last year[6] - Net profit attributable to shareholders was CNY 14,994,496.83, down 37.38% from CNY 23,944,713.73 year-on-year[6] - Total revenue for Q1 2025 was CNY 479,926,834.64, a decrease of 16.5% compared to CNY 574,528,830.84 in Q1 2024[22] - Operating profit for Q1 2025 was CNY 20,881,969.61, a decline of 34.3% compared to CNY 31,746,214.60 in Q1 2024[22] - The net profit for Q1 2025 was 15,717,573.30, a decrease of 37.4% compared to 25,123,136.63 in Q1 2024[23] - The company reported a total comprehensive income of 11,347,415.04 for Q1 2025, down 55.2% from 25,346,836.31 in Q1 2024[23] Cash Flow - The net cash flow from operating activities was negative at CNY -28,774,798.16, a decline of 167.22% compared to CNY 42,806,771.33 in the previous year[6] - The total revenue from operating activities in Q1 2025 was 392,984,135.62, down 23.4% from 512,993,663.80 in Q1 2024[26] - The net cash flow from operating activities for Q1 2025 was -28,774,798.16, compared to 42,806,771.33 in Q1 2024, indicating a significant decline[26] - The company incurred a cash outflow of 421,758,933.78 from operating activities in Q1 2025, compared to 470,186,892.47 in Q1 2024[26] - The net cash flow from financing activities for Q1 2025 was 37,211,883.85, a significant increase from 1,092,398.13 in Q1 2024[27] - The cash inflow from investment activities was -12,618,745.39 for Q1 2025, compared to -2,248,081.46 in Q1 2024, indicating increased cash outflow[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,122,566,299.08, a slight increase of 0.22% from CNY 3,115,812,628.78 at the end of the previous year[6] - Total assets as of March 31, 2025, amounted to CNY 3,122,566,299.08, compared to CNY 3,115,812,628.78 at the end of 2024[19] - Total liabilities decreased to CNY 672,411,521.45 as of March 31, 2025, from CNY 689,005,266.19 at the end of 2024[19] - Shareholders' equity attributable to the parent company increased by 0.45% to CNY 2,373,662,839.07 from CNY 2,363,038,500.50 at the end of the previous year[6] - Shareholders' equity increased to CNY 2,450,154,777.63 as of March 31, 2025, from CNY 2,426,807,362.59 at the end of 2024[19] Research and Development - Research and development expenses decreased by 14.55%, indicating a reduction in R&D investment compared to the previous year[7] - Research and development expenses for Q1 2025 were CNY 7,656,280.53, down from CNY 8,960,100.75 in Q1 2024[22] Other Financial Metrics - Basic and diluted earnings per share decreased by 25.00% to CNY 0.03 from CNY 0.04 in the same period last year[6] - Basic earnings per share for Q1 2025 were 0.03, a decrease from 0.04 in Q1 2024[23] - The company reported a net impairment loss of CNY 3,910,182.42 in Q1 2025, compared to a gain of CNY 90,360.00 in Q1 2024[22] - The company reported a decrease in other comprehensive income, with a net amount of -4,370,158.26 for Q1 2025 compared to 223,699.68 in Q1 2024[23] Future Plans - The company plans to focus on market expansion and new product development in the upcoming quarters[15] Government Subsidies - The company received government subsidies amounting to CNY 281,045.50 during the reporting period[8] Prepayments and Contract Liabilities - The company reported a significant increase in prepayments by 39.57%, primarily due to advance payments for Chinese medicinal materials[7] - Contract liabilities rose by 59.92%, attributed to the receipt of advance payments for goods[7]